EcoDrugPlus

Aph-1 Homolog A, Gamma-Secretase Subunit

Ensembl ID : ENSBTAG00000021482
Gene Symbol: APH1A
14 Enzyme and pathways 5 Cross references
150 Possible Orthologues:

Aph-1 Homolog B, Gamma-Secretase Subunit

Ensembl ID : ENSBTAG00000010641
Gene Symbol: APH1B
14 Enzyme and pathways 5 Cross references
205 Possible Orthologues:

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSBTAG00000002745
Gene Symbol: APEX1
9 Enzyme and pathways 5 Cross references
219 Possible Orthologues:

Arachidonate 12-Lipoxygenase, 12s Type

Ensembl ID : ENSBTAG00000021933
Gene Symbol: ALOX12
13 Enzyme and pathways 5 Cross references
205 Possible Orthologues:

Arachidonate 5-Lipoxygenase

Ensembl ID : ENSBTAG00000020319
Gene Symbol: ALOX5
23 Enzyme and pathways 5 Cross references
234 Possible Orthologues:

Arachidonate 5-Lipoxygenase Activating Protein

Ensembl ID : ENSBTAG00000013201
Gene Symbol: ALOX5AP
8 Enzyme and pathways 5 Cross references
215 Possible Orthologues:

Arginine Vasopressin Receptor 1a

Ensembl ID : ENSBTAG00000007175
Gene Symbol: AVPR1A
8 Enzyme and pathways 5 Cross references
280 Possible Orthologues:

Arginine Vasopressin Receptor 1b

Ensembl ID : ENSBTAG00000017301
Gene Symbol: AVPR1B
8 Enzyme and pathways 5 Cross references
146 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSBTAG00000047138
Gene Symbol: AVPR2
15 Enzyme and pathways 5 Cross references
262 Possible Orthologues:

Aryl Hydrocarbon Receptor

Ensembl ID : ENSBTAG00000007746
Gene Symbol: AHR
7 Enzyme and pathways 4 Cross references
167 Possible Orthologues:

Aurora Kinase A

Ensembl ID : ENSBTAG00000013009
Gene Symbol: AURKA
19 Enzyme and pathways 5 Cross references
253 Possible Orthologues:

Aurora Kinase B

Ensembl ID : ENSBTAG00000001717
Gene Symbol: AURKB
32 Enzyme and pathways 5 Cross references
217 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).